{
  "Clinical Information": [],
  "Patent Information": [],
  "Sequence Information": {
    "ID": "AP04208",
    "Peptide Name": "C14R (derivative of BP100, synthetic AMPs, Arg-rich)",
    "Source": "designed",
    "Family": "Not found",
    "Gene": "Not found",
    "Sequence": "CSSGSLWRLIRRFLRR",
    "Sequence Length": 16,
    "UniProt Entry": "Ref",
    "Protein Existence": "Not found",
    "Biological Activity": [
      "Anti-Gram-",
      "Antifungal",
      "candidacidal"
    ],
    "Target Organism": "Not found",
    "Hemolytic Activity": "Not found",
    "Cytotoxicity": "Not found",
    "Binding Target": "Not found",
    "Linear/Cyclic": "Not found",
    "N-terminal Modification": "Not found",
    "C-terminal Modification": "Not found",
    "Nonterminal Modifications and Unusual Amino Acids": "Not found",
    "Stereochemistry": "Not found",
    "Structure": "Unknown",
    "Structure Description": "Not found",
    "Helical Wheel Diagram": "Not found",
    "PDB ID": "",
    "Predicted Structure": "Not found",
    "Formula": "Not found",
    "Absent Amino Acids": "Not found",
    "Common Amino Acids": "Not found",
    "Mass": "Not found",
    "PI": "Not found",
    "Basic Residues": "Not found",
    "Acidic Residues": "Not found",
    "Hydrophobic Residues": "Not found",
    "Net charge": 5,
    "Boman Index": 3.59,
    "Hydrophobicity": "Not found",
    "Aliphatic Index": "Not found",
    "Half Life": "Not found",
    "Extinction Coefficient Cystines": "Not found",
    "Absorbance 280nm": "Not found",
    "Polar Residues": "Not found",
    "Function": "Not found",
    "Hydrophobic residue%": "44%",
    "Crucial residues": ""
  },
  "Literature Information": {
    "Literature": "Sequence analysis: APD analysis reveals that this sequence is most similar (47.06%) toGLRC-6R: 31%; L=S: 19%.Activity: 99 clinical isolates C. albicans (MIC 0.391-100 ug/ml: mode 3.125 ug/ml, ECV 95%: 12.5 ug/ml. cf: ref strain C. albicans ATCC 10231 MIC 6.25 ug/ml), 106 clinical isolates C. auris (MIC 0.391-100 ug/ml: mode: 6.25 ug/ml; ECV 95%: 25 ug/ml) (Vélez et al., 2024). Radial diffusion assay: inhibited 6 clinical strains P. aeruginosa (dose-dependent 12.5-100 ug/ml).Structure:  alphafold predicted helical structure (Mildenberger et al., 2024).Peptide formulation: it has been formulated in hydrogel wound dressing that controls P. aeruginosa.",
    "Author": "Kraemer M, Bellion M, Kissmann AK, Herberger T, Synatschke CV, Bozdogan A, Andersson J, Rodriguez A, Ständker L, Wiese S, Stenger S, Spellerberg B, Gottschalk KE, Cetinkaya A, Pietrasik J, Weil T, Rosenau F.2023",
    "Reference": "Int J Mol Sci. 2023 Mar 2;24(5):4800. doi: 10.3390/ijms24054800.PubMed",
    "Title": "Aptamers as Novel Binding Molecules on an Antimicrobial Peptide-Armored Composite Hydrogel Wound Dressing for Specific Removal and Efficient Eradication of Pseudomonas aeruginosa."
  },
  "3D Structure": []
}